Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
The Oncologist · 06.04.2023 · 28 (4) · e191-e197
DOI: 10.1093/oncolo/oyac271 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 13.02.2023. Verfasst von Yongjian Zhou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Abstract (Originalsprache)
Background
Anlotinib is a multi-target tyrosine kinase inhibitor that can effectively inhibit tumor cell proliferation after receptor kinase activation caused by KIT gene mutation.
Methods
We tested the inhibitory effect of anlotinib in GIST cell lines with different gene mutations and evaluated the efficacy of anlotinib for patients with metastatic GIST after imatinib failure in a multicenter, single-arm, phase II study.
Results
In vitro, V654A mutation encoded by KIT exon 13 was intermediately sensitive to anlotinib. Moreover, anlotinib was able to partly suppress the activation loop mutation D820A from exon 17 while another activation loop mutation N822K, also from exon 17, was resistant to anlotinib. From September 2018 to October 2020, 64 patients from 9 Chinese medical centers were enrolled in this study. Seven patients had partial response and 39 patients had stable disease. The median PFS was 8.0 months. There was no statistical significance comparing with PFS of sunitinib second-line therapy at the same period. The most common adverse events related to anlotinib treatment were hypertension, neutropenia, and fatigue.
Conclusion
Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, People's Republic of China.
- CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
- Department of Internal Medicine, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu, People's Republic of China.
- Department of Gastrointestinal Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
- The Second Ward of Gastroenterology Department, Harbin Medical University Cancer Hospital, Heilongjiang, People's Republic of China.
- Department of Gastrointestinal Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangdong, People's Republic of China.
ORCID-Profile: Yuexiang Wang
Förderung
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Zitieren
APA
Zhou, Y., Zeng, C., Sun, X., Zhang, J., Qu, H., Zhang, X., Zhou, Y., Liu, Z., Wu, X., Wu, X., Jiao, X., Shen, L., Zhou, Y., Wang, Y., & Li, J. (2023). Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study. The Oncologist, 28(4), e191-e197. https://doi.org/10.1093/oncolo/oyac271
Vancouver
Zhou Y, Zeng C, Sun X, Zhang J, Qu H, Zhang X, et al. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study. The Oncologist. 2023;28(4):e191-e197. doi:10.1093/oncolo/oyac271
BibTeX
@article{Zhou2023,
author = {Zhou, Yongjian and Zeng, Chunling and Sun, Xiaofeng and Zhang, Jun and Qu, Hongyan and Zhang, Xinhua and Zhou, Ye and Liu, Zimin and Wu, Xiaojun and Wu, Xin and Jiao, Xuelong and Shen, Lin and Zhou, Yanbing and Wang, Yuexiang and Li, Jian},
title = {Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {4},
pages = {e191--e197},
doi = {10.1093/oncolo/oyac271}
}
EUVIMED